[
    "{\"step_by_step_thinking\": \"Dupilumab is a monoclonal antibody that targets interleukin-4 receptor alpha (IL-4R\u03b1), which is involved in the inflammatory response in asthma. It is approved for the treatment of moderate-to-severe asthma in patients aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. Clinical trials have shown that dupilumab can reduce exacerbations, improve lung function, and reduce the need for oral corticosteroids in patients with asthma. Therefore, the answer is A. yes.\", \"answer_choice\": \"A\"}"
]